Feasibility and clinical safety of cytokine-activated anti-tumor lymphocytes infusion in dogs with diffuse large B-cell lymphoma: a pilot study
Journal of Veterinary Internal Medicine · 02.11.2026 · 40 (6)
DOI: 10.1093/jvimsj/aalag299 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, online erschienen am 20.11.2026. Verfasst von Sonia Capellero und 10 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione Piemontese per la Ricerca sul Cancro, Italian Ministry of Health, INOC—Istituto Nazionale Oncologico Candiolo FPRC ETS 5 per mille.
Abstract (Originalsprache)
Background
Diffuse large B-cell lymphoma (DLBCL) is the most common histologic subtype of lymphoma in dogs. Although using cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy is the standard treatment, outcomes remain suboptimal, emphasizing the need for novel therapeutic strategies. Hypothesis/Objectives Evaluate the feasibility and potential therapeutic benefit of adoptive immunotherapy using ex vivo-expanded cytokine-activated anti-tumor lymphocytes (CATLs) in dogs with DLBCL treated using CHOP chemotherapy and an autologous tumor vaccine. Animals Seven client-owned dogs with naturally occurring DLBCL.
Methods
Dogs received CHOP-based chemotherapy and the APAVAC® autologous vaccine. Peripheral blood mononuclear cells (PBMCs) were expanded ex vivo for 14 days using interleukin-2 and anti-CD3/CD28 stimulation. The CATLs were characterized by flow cytometry and reinfused.
Results
Peripheral blood mononuclear cells were successfully expanded. After 14 days, the median cell yield was 728 × 106 cells (range, 162.4 × 106-1 500 × 106), corresponding to a median 8.6-fold expansion. Median fold increases of positive cells were 7.23 (interquartile range [IQR], 6.46-9.64) for CD3+, 8.56 (IQR, 7.11-14.56) for CD4+, 8.41 (IQR, 6.24-9.29) for CD5+, 10.35 (IQR, 7.63-14.67) for CD8+, and 16.16 (IQR, 12.22-30.40) for CD4+CD8+ cells. Reinfused CATLs ranged from 162.4 × 106 to 1 500 × 106 cells. Conclusions and clinical importance Ex vivo expansion and reinfusion of autologous CATLs in dogs with DLBCL receiving CHOP chemotherapy and APAVAC® vaccination are feasible and induce robust T-cell expansion, suggesting this combined chemo-immunotherapeutic approach may enhance anti-tumor immunity and warrants further investigation in larger clinical studies.
Förderung
- Fondazione Piemontese per la Ricerca sul Cancro
- Italian Ministry of Health
- INOC—Istituto Nazionale Oncologico Candiolo FPRC ETS 5 per mille
Zitieren
APA
Capellero, S., Maga, I., Donini, C., Galiazzo, E., Sapino, A., Maria, R. D., Leuci, V., Massa, A., Sangiolo, D., Marconato, L., & Aresu, L. (2026). Feasibility and clinical safety of cytokine-activated anti-tumor lymphocytes infusion in dogs with diffuse large B-cell lymphoma: a pilot study. Journal of Veterinary Internal Medicine, 40(6). https://doi.org/10.1093/jvimsj/aalag299
Vancouver
Capellero S, Maga I, Donini C, Galiazzo E, Sapino A, Maria RD, et al. Feasibility and clinical safety of cytokine-activated anti-tumor lymphocytes infusion in dogs with diffuse large B-cell lymphoma: a pilot study. Journal of Veterinary Internal Medicine. 2026;40(6). doi:10.1093/jvimsj/aalag299
BibTeX
@article{Capellero2026,
author = {Capellero, Sonia and Maga, Ilaria and Donini, Chiara and Galiazzo, Erika and Sapino, Anna and Maria, Raffaella De and Leuci, Valeria and Massa, Annamaria and Sangiolo, Dario and Marconato, Laura and Aresu, Luca},
title = {Feasibility and clinical safety of cytokine-activated anti-tumor lymphocytes infusion in dogs with diffuse large B-cell lymphoma: a pilot study},
journal = {Journal of Veterinary Internal Medicine},
year = {2026},
volume = {40},
number = {6},
doi = {10.1093/jvimsj/aalag299}
}
EUVIMED